【24h】

Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers.

机译:在人类癌症中胰腺十二指肠同源盒1的组织微阵列分析。

获取原文
获取原文并翻译 | 示例
           

摘要

In previous studies, we demonstrated that rat insulin promoter (RIP)-driven gene therapy successfully targeted human pancreatic tumor PANC-1 cells and mouse insulinoma NIT-1 cells, which are both pancreatic duodenal homeobox-1 (PDX-1)-positive. The purpose of this study was to perform a human tissue array analysis to determine potential targets for RIP-driven gene therapy. A custom-designed tissue MicroArray analysis of various human cancer specimens was performed using a PDX-1 polyclonal antibody generated in our laboratory. The custom-designed Tissue MicroArray of human tumor specimens consists of human cancer specimens from different origins, such as the pancreas, breast, colon, prostate, kidney, liver, lung, and ovary. A panel of normal human specimens from 20 organs or tissues was used as a control. All tissues were fixed in formalin and embedded in paraffin. The immunohistochemistry studies of the cytoplasm and the nuclear expression levels were compared using the Loda method and blind reviews. Data are presented as the mean +/- SEM (p < 0.05 was considered significant by the unpaired student t-test). PDX-1 expression intensity was elevated in both benign and malignant tissues from the same patient with pancreas, breast, colon, prostate, and kidney cancers, whereas normal human tissues from control subjects without cancer did not express PDX-1. These results suggest that PDX-1 is an early marker for these cancers and could be potentially used as a diagnostic parameter and perhaps could be targeted by PDX-1-activated gene therapies, such as RIP-TK.
机译:在以前的研究中,我们证明了大鼠胰岛素启动子(RIP)驱动的基因治疗成功地靶向了人胰腺癌PANC-1细胞和小鼠胰岛素瘤NIT-1细胞,两者均为胰腺十二指肠同源盒1(PDX-1)阳性。这项研究的目的是进行人体组织分析,以确定RIP驱动基因治疗的潜在靶标。使用我们实验室产生的PDX-1多克隆抗体对各种人类癌症标本进行了定制设计的组织微阵列分析。定制设计的人类肿瘤标本组织微阵列包括来自不同来源的人类癌症标本,例如胰腺,乳腺癌,结肠癌,前列腺癌,肾癌,肝癌,肺癌和卵巢癌。使用一组来自20个器官或组织的正常人类标本作为对照。将所有组织固定在福尔马林中并包埋在石蜡中。使用Loda方法和盲法审查比较了细胞质和核表达水平的免疫组织化学研究。数据以平均值+/- SEM表示(p <0.05被未配对的学生t检验视为显着)。来自患有胰腺癌,乳腺癌,结肠癌,前列腺癌和肾癌的同一患者的良性和恶性组织中的PDX-1表达强度均升高,而来自未患癌症的对照受试者的正常人组织中未表达PDX-1。这些结果表明,PDX-1是这些癌症的早期标志物,可以潜在地用作诊断参数,并且可能被PDX-1激活的基因疗法(如RIP-TK)作为目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号